Obesity Player Raising More Capital (ETRM)

December 9, 2010 · Filed Under Cardiac, Diabetes, Financial, obesity · Comment 

EnteroMedics Inc. (NASDAQ: ETRM) is raising more capital than had been previously disclosed and its shares are getting hit as a result.  The company which focuses on devices using neuroblocking technology now plans to sell more shares and warrants.

The company is raising R&D funds for the commercialization of its obesity treatment. It is selling 14.8 million shares and warrants, higher than the 12 million previously disclosed.  The price is at $1.75, with a warrant exercise price of $2.19 per share.

As far as how this compares to the float and dilution, that is rather large because the float was said to be only about 7.5 million shares before this offering.

After the obesity treatment news from Orexigen (NASDAQ: OREX) this week, the hiked offering may be less of a surprise.  Here is the problem: shares closed at $2.21 yesterday.  The early indications have EnteroMedics shares down over 12% at $1.93 and the 52-week trading range is $1.52 to $8.64.  The market cap here was a mere $16.5 million as of yesterday.

JON C. OGG

Bill Gates, Small Biotech's New Biggest Investor (ALTH, AMAG, RDEA, ARYX, AUXL, BMRN, ETRM, INCY, ITMN, MAPP, OREX, VRUS, REGN, SGEN, VRTX, XNPT)

May 16, 2009 · Filed Under General · Comments Off 

Late yesterday came the 13-F quarterly filing from the Bill & Melinda Gates Foundation Trust.  Bill and Melinda have invested in drugs and research before, as well as dug companies, but there was a slew of biotech stocks in their quarterly holdings.  Some of these are cancer winners, while others may seem random.  Below we have broken these out by company and size of the position in dollars (M for million; K for thousand) as well as the number of shares.

ALLOS THERAPEUTICS INC. (NASDAQ: ALTH) $3.090M; 500,000 shares
AMAG PHARMACEUTICALS INC. (NASDAQ: AMAG) $1.839M; 50,000 shares
ARDEA BIOSCIENCES INC. (NASDAQ: RDEA) $2.165M; 210,386 shares
ARYX THERAPEUTICS INC. (NASDAQ: ARYX) $1.635M; 480,799 shares
AUXILIUM PHARMACEUTICALS INC. (NASDAQ: AUXL) $2.062M; 74,400 shares
BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) $1.295M; 104,856 shares
ENTEROMEDICS INC. (NASDAQ: ETRM) $81K; 59,700 shares
INCYTE CORP. (NASDAQ: INCY) $1.02M; 435,700 shares
INTERMUNE INC. (NASDAQ: ITMN) $1.807M; 109,900 shares
MAP PHARMACEUTICALS INC. (NASDAQ: MAPP) $98K; 46,524 shares
OREXIGEN THERAPEUTICS INC. (NASDAQ: OREX) $36K; 13,900 shares
PHARMASSET INC. (NASDAQ: VRUS) $821K; 83,641 shares
REGENERON PHARMACEUTICALS (NASDAQ: REGN) $492K; 35,500 shares
SEATTLE GENETICS INC. (NASDAQ: SGEN) $34.718M; 3,521,088 shares
VERTEX PHARMACEUTICALS INC. (NASDAQ: VRTX) $2.729M; 95,000 shares
XENOPORT INC. (NASDAQ: XNPT) $2.517M; 130,000 shares

Read more

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed